John Wyckoff has been named the new director of the Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) at Colorado State University.
Wyckoff will lead BioMARC, a nonprofit contract manufacturing operation owned and operated by CSU to produce vaccines, therapeutics, diagnostics, and other biopharmaceutical products. In this role, he will oversee operations relating to CSU’s research expertise in translational medicine in the Infectious Disease Research Center and the greater CSU community.
“John’s extensive background in both academic research and private industry research will bring a new dimension to what we can provide through the BioMARC operation,” said Ray Goodrich, executive director of the Infectious Disease Research Center. “His experience with translational research will help us to expand our reach in providing new product development opportunities for faculty as well as external academic, government and private sector organizations developing products of great public value and need.”
Background in industry and academics
Wyckoff comes to CSU with experience in both academic and industrial research. After receiving his Ph.D. in Veterinary Parasitology and Immunology from the University of Florida, he spent nearly 20 years as a professor of immunology at the College of Veterinary Medicine at Oklahoma State University, where his research focused on Brucella. Wyckoff built the first Biosafety Level 3 lab at Oklahoma State.
After leaving OSU in 2008, Wyckoff served as the director of research projects at Merial and most recently as the associate director of companion animal biologics research and development for Boehringer Ingelheim VetMedica Inc.
His work in the corporate world focused on the development of veterinary vaccine formulations. He has licensed more than a dozen products, including vaccines for rabies in cats, Lyme disease in dogs, dog flu and Bordetella.
Wyckoff’s new position with BioMARC will allow him to continue to develop strategic partnerships needed to accelerate manufacturing and commercialization of biologic products, from the bench to the bedside.
“We are pleased to have John as a member of our team, focused on education and research programs that benefit both human and animal patients on a global basis,” said Goodrich.
Colorado State University, as an institution, has been at the forefront of microbial research since its inception over 100 years ago. Past research experience coupled with industry expertise led to the successful establishment of BioMARC in 2006. It is housed in the Infectious Disease Research Center under the Office of the Vice President for Research at Colorado State.
BioMARC’s vision is to provide quality, service, and commitment to help people live life to its greatest potential through biopharmaceutical product discovery and development.